IPOs & Markets
Impact is offering 41.98 million shares at HK$19.75-21.75 each.
1
China's Impact Therapeutics eyes up to $117m in Hong Kong IPO
2
Nasdaq-listed MoneyHero hits first profit on 27% revenue growth, cost cuts
3
UVM Signum scores outsized returns as SBI Group backs Startale
4
Singapore AI startup ReN3 scores $5m funding and other SE Asia deals
5
Secondaries market sees steady innovation and broader adoption as a portfolio tool: Azalea
More Stories
[Updated] Malaysia’s Avisena explores fundraise as healthcare deals flood market
Singapore’s Silicon Box raises $150m, EDBI joins cap table
Google, VNG launch Applied AI Lab to accelerate Vietnam’s AI capabilities
SE Asia startup funding stays thin in Q1 2026 even as agentic and GenAI gain ground
Aura Private Equity, WICapital re-up in Philippines fintech Giftaway
Earnings and Results
The Singapore-based company posted a net profit of $5 million in Q4 2025.
Deals
UVM Signum first backed Startale in January 2024.
Venture Capital
The round was anchored by Vertex Ventures SE Asia & India.
Secondaries
“There is a growing structural acceptance of secondaries as a portfolio management and liquidity tool.”
World
Blackstone Digital Infrastructure Trust is offering 87.5 million shares.
Singapore
Grab expects revenue of $4.04-4.1b in 2026, representing 20–22% growth.
Group has added Infinity Financial Advisory, SG Alliance, and PromiseLand Financial Advisory to its network.
Indonesia
The transaction is expected to increase OCBC Indonesia’s AUM by 25%.
India
Fund V is targeting a total corpus of $225 million.
